Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

Urology

Volumn 52, Issue 4, 1998, Pages 637-640

  Sweat, Susan D ^b   Pacelli, Anna ^b   Murphy, Gerald P ^b   Bostwick, David G ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ANTIGEN EXPRESSION; ARTICLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS;

EID: 0032188742     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00278-7     Document Type: Article

References (24)

1. Horoszewicz JS, Kawinski E, and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-936, 1987.
2. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998.
3. Troyer JK, Beckett ML, and Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30: 232-242, 1997.
4. Fair WR, Israeli RS, and Heston WDW: Prostate-specific membrane antigen. Prostate 32: 140-148, 1997.
5. Israeli R, Grob M, and Fair W: Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Urol Clin North Am 24: 439-450, 1997.
6. Barren RJ III, Holmes EH, Boynton AL, et al: Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30: 65-68, 1997.
7. Pinto JT, Suffoletto BP, Berzin TM, et al: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 21: 1445-1451, 1996.
8. Israeli R, Powell CT, Corr JG, et al: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994.
9. 90Y-CYT-356: a new prostatic cancer therapeutic agent (abstract). J Urol 147: 361A, 1992.
10. Gao X, Porter A, Grignon DJ, et al: Diagnostic and prognostic markers for human prostate cancer. Prostate 31: 264-281, 1997.
11. 111indium-labeled monoclonal antibody CYT-356. J Urol 152: 1952-1955, 1994.
12. Murphy GP, Maguire RT, Rogers B, et al: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 33: 281-285, 1997.
13. Zuckier LS, and DeNardo GL: Trials and tribulations: oncological antibody imaging comes to the lore. Semin Nucl Med 27: 10-29, 1997.
14. Bostwick DG, and Montironi R: Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Virchows Arch 430: 1-16, 1997.
15. Bostwick DG, Pacelli A, Blute M, et al: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: study of 184 cases. Cancer 82: 2256-2261, 1998.
16. Wright GL, Haley C, Beckett ML, et al: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1: 18-28, 1996.
17. Silver DA, Pellicer 1, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-85, 1997.
18. Wright GL Jr, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334, 1996.
19. Troyer JK, Beckett ML, and Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-558, 1995.
20. Lopes AD, Davis WL, Rosenstraus MJ, et al: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7311-C5. Cancer Res 50: 6423-6429, 1990.
21. Burgers JK, Hinkle GH, and Haseman MK: Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 13: 103-112, 1995.
22. Rochon YP, HoroszewiczJS, Boynton AL, et al: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 25: 219-223, 1994.
23. Murphy GP, Holmes EH, Boynton AL, et al: Comparison of prostate specific antigen, prostate specific membrane antigen, and LN CaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 26: 164-168, 1995.
24. Murphy GP, Radge H, Kenny GM, et al: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 15: 1473-1480, 1995.